局部区域复发分化型甲状腺癌主动监测的系统综述与荟萃分析
该系统综述与荟萃分析纳入10项回顾性研究共841例完全切除原发肿瘤后出现局部区域复发或淋巴结转移的分化型甲状腺癌患者,评估主动监测期间的疾病进展率。汇总进展率为23%(95%CI 12-34%),活检证实病例为32%(95%CI 15-55%),校正随访丢失后估计可达35-70%。基线血清甲状腺球蛋白升高和晚期肿瘤分期与更高进展风险相关。
要点
- 局部区域复发DTC主动监测的汇总进展率为23%,活检证实者达32%。
- 随访不足40个月的研究进展率更高(36% vs 17%,p<0.05)。
- 基线Tg升高和晚期分期患者进展风险更高,需密切监测。
核心结论
- 局部区域复发分化型甲状腺癌主动监测的进展率可能因异质性和随访丢失被低估,应谨慎考虑。
- 基线血清甲状腺球蛋白升高和晚期肿瘤分期患者进展率更高,可能有助于识别需密切监测或早期干预的患者。
研究设计与样本
- 系统综述与荟萃分析,检索MEDLINE、EMBASE和COCHRANE数据库至2025年7月。
- 纳入10项回顾性研究,共841例完全切除原发肿瘤后局部区域复发(甲状腺床结节或淋巴结转移)的分化型甲状腺癌患者。
- 采用随机效应模型计算汇总进展率,并进行亚组、敏感性和meta回归分析,同时校正随访丢失。
主要发现
- 汇总平均随访时间为51.6个月(95%CI 36.0-67.2)。
- 10项研究的总体汇总进展率为23%(95%CI 12-34%),活检证实病例为32%(95%CI 15-55%)。
- 平均随访<40个月的研究进展率高于≥40个月者(36% vs 17%,p<0.05)。
- 进展组基线血清甲状腺球蛋白对数转换值显著高于稳定组(1.02 vs -0.07,p<0.05)。
- Stage I患者<75%的研究进展率更高(30% vs 11%,p<0.05),Stage IV患者≥5%的研究进展率更高(28% vs 14%,p<0.05)。
临床怎么用
- 对局部区域复发DTC考虑主动监测时应谨慎,尤其存在基线Tg升高或晚期分期时。
- 基线血清甲状腺球蛋白水平和肿瘤分期可能有助于分层选择密切监测或早期干预的患者。
局限性
- 纳入研究均为回顾性设计,存在异质性和随访丢失。
- 随访丢失可能导致进展率被低估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Active surveillance (AS) has been proposed as a management option for recurrence of thyroid cancer. However, the current evidence for AS remains limited because of retrospective study designs, small sample sizes, and follow-up loss. We therefore performed a systematic review and meta-analysis to provide a more reliable estimate of disease progression during AS for recurrent thyroid cancers. METHODS: This systematic review is reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. We searched MEDLINE, EMBASE, and COCHRANE databases through July 2025. Eligible studies included patients with recurrent thyroid cancer (thyroid bed nodules or lymph node metastases) managed with AS after complete resection of the primary tumor. Pooled progression rates were calculated using a random-effects model, with subgroup, sensitivity, and meta-regression analyses also being performed. Progression rates were also adjusted using modeling for follow-up loss. RESULTS: Ten retrospective studies (n = 841) were included. All included lesions were locoregional metastases from differentiated thyroid cancer (DTC). The pooled mean follow-up duration was 51.6 months (95% confidence interval [CI], 36.0-67.2). Across 10 studies, the overall pooled progression rate was 23% [95% CI, 12-34%] and was higher in biopsy-confirmed cases (32%; 95% CI, 15-55%). Progression was higher in studies with <40 months of mean follow-up than in studies with ≥40 months of mean follow-up (36% vs. 17%, p < 0.05). Log-transformed baseline serum thyroglobulin levels were significantly higher in the progression group compared with the stable group (1.02 vs. -0.07, p < 0.05). Subgroup analyses revealed higher progression rates in studies with <75% Stage I patients (30% vs. 11%, p < 0.05) and with ≥5% Stage IV patients (28% vs. 14%, p < 0.05). Adjustment for follow-up loss increased the estimated pooled progression rate up to 35-70%. CONCLUSIONS: Reported progression rates of AS for locoregional recurrent DTC may be underestimated due to heterogeneity and follow-up loss. Consequently, AS should be considered with caution. Higher progression rates were observed in patients with elevated baseline serum thyroglobulin levels and advanced tumor stage, suggesting that these factors may help identify patients who require closer monitoring or earlier intervention.
引用
- Lim H, Cho SJ, Baek JH, et al. Active Surveillance for Locoregional Recurrent Differentiated Thyroid Cancer: A Systematic Review and Meta-Analysis. Thyroid. 2026. PMID: 41791888. doi:10.1177/10507256251412323
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。